We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > gilead

News List

Gilead Sciences’ MAA for chronic hepatitis C therapy validated in Europe pharmaceutical-technology
January 25, 2017
The European Medicines Agency (EMA) has validated Gilead Sciences’ marketing authorisation application (MAA) for investigational Chronic Hepatitis C Therapy Sofosbuvir / Velpatasvir / Voxilaprevir (SOF / VEL / VOX).
EMA validates Gilead’s MAA for investigational chronic Hep C therapy cphi-online
January 24, 2017
Sofosbuvir/Velpatasvir/Voxilaprevir cranted an accelerated assessment by the EMA.
How Would Gilead Keep Its Status With the Increasing Downward Pressure on Revenue Expectations? en-cphi.cn
January 06, 2017
Gilead has dominated the HCV drug market for years with unshakeable “absolute supremacy” since its new direct-acting antiviral (DAA) Sovaldi entered the market in December 2013.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page